Anti-HIV drugs statements include references to the demand for our Trofile Assay healthy.
Forward-Looking Statements – Certain statements in this press release are forward-looking statements. Anti-HIV drugs statements include references to the demand for our Trofile Assay, the potential use of our Trofile Assay for patient selection for the class of anti-HIV drugs such as CCR5 antagonists are known, using the magnitude and timing of our customers’ clinical trials of our products, the outlook for the CCR5 class of drugs and our Trofile assay, the number of patients per year in the U.S healthy ., possibly candidates for new classes of anti-HIV drugs such as CCR5 antagonists, expected protection provided by patents, possible regulation of Trofile be could and our other products by the FDA. These statements may involve risks and uncertainties and other factors that may cause actual results to differ materially from the anticipated results or other be expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may have a molecular diagnostics for patient selection for CCR5 antagonists or other anti-HIV drugs whether larger confirmatory clinical studies will of the first studies of the first studies, risks and uncertainties relating to the performance of our products, the growth in revenues, the size, timing and success or failure of any clinical trials for CCR5 inhibitors Entry inhibitors or integrase inhibitors the risk that our Trofile assay may not be for patient use with CCR5 inhibitors used to obtain our ability to successfully conduct clinical studies and the results of these studies, our ability to reliable, high-volume operations at commercially acceptable costs create; expected dependence on a few customers for the majority of our revenues, the annual renewal of certain customer agreements that actual markets market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies, our estimate of the size of our, our estimate of the demand for our products, the impact of competition, the timing and ultimate size of the pharmaceutical company clinical trials, whether decide the FDA or any other agency, further regulation of our products or services, including Trofile;, whether liable to pay reimbursement for our products and services and the amount of such refund, are permitted if the design is issued guidelines for Multivariate Index assays from subsequently determined subsequently determined to apply to our current or planned products, whether problems problems or delays in automation our processes and the ultimate validity and enforceability of our patent applications and patents, the possible violation of the intellectual property of others, if we licenses for technologies developed by others will be available if we are revenue able to build brand loyalty and expand; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt contracts that converted impact of additional dilution if our convertible is in equity, and whether we will be able to raise sufficient funds to increase in the future, if necessary. For a discussion of other factors that could cause differ from those projected differ from those projected, please refer to our most recent annual report on Form 10 – K and quarterly reports on Form 10-Q , and other subsequent filings with the Securities and Exchange Commission. We assume no obligation, and expressly disclaim any obligation to update any forward-looking the occurrence of the occurrence of anticipated or unanticipated events or circumstances after the date of these statements reflect. Trofile and PhenoSense GT are trademarks of Monogram Biosciences,Monogram Biosciences. (more…)